**Association of Chronic Kidney Disease With the Spectrum of Ankle Brachial Index**

**The CHS (Cardiovascular Health Study)**

Joachim H. Ix, MD, MAS,*†§ Ronit Katz, DP HIL,‡ Brian R. Kestenbaum, MD, MS,¶ Matthew A. Allison, MD, MPH,† David S. Siscovick, MD, MPH,∥ Anne B. Newman, MD, MPH,** Mark J. Sarnak, MD, MS,†† Michael G. Shlipak, MD, MPH,‡‡§§ Michael H. Criqui, MD, MPH†‡

**San Diego and San Francisco, California; Seattle, Washington; Pittsburgh, Pennsylvania; and Boston, Massachusetts**

**Objectives**

This study sought to determine the association of chronic kidney disease (CKD) with high ankle brachial index (ABI) measurement and to compare its strength with that of CKD with a low ABI.

**Background**

CKD is an important risk factor for cardiovascular disease (CVD) events. A high ABI, a marker of lower extremity arterial stiffness, is associated with CVD events and mortality. The association between CKD and high ABI is unknown.

**Methods**

The CHS (Cardiovascular Health Study) enrolled community-living people ≥65 years of age and measured kidney function and ABI. Glomerular filtration rate (GFR) was estimated using equations that incorporated either cystatin C or creatinine, and CKD was defined by estimated GFR < 60 ml/min/1.73 m². The ABI was categorized as low (<0.90), low-normal (0.90 to 1.09), normal (1.10 to 1.40), and high (>1.40 or incompressible). Multinomial logistic regression was used to evaluate the associations of CKD with ABI categories.

**Results**

Among 4,513 participants, 23% had CKD, 13% had a low ABI, and 3% had a high ABI. In models adjusted for age, sex, race, hypertension, diabetes, smoking, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and C-reactive protein, cystatin C-based CKD was associated with both low ABI (relative risk [RR]: 2.0; 95% confidence interval [CI]: 1.6 to 2.5; p < 0.001) and high ABI (RR: 1.6; 95% CI: 1.0 to 2.3; p = 0.03). Results were similar when CKD was defined by creatinine.

**Conclusions**

CKD is associated with both the high and the low extremes of ABI in community-living older people. Future studies should evaluate whether arterial stiffness is an important mechanism leading to CVD in people with CKD.

(J Am Coll Cardiol 2009;54:1176–84) © 2009 by the American College of Cardiology Foundation

Chronic kidney disease (CKD) affects approximately 13% of adults in the U.S. (1), and is strongly associated with cardiovascular disease (CVD) events and all-cause mortality (2). These associations are not fully explained by traditional CVD risk factors, and are detected even with modest decrements in kidney function (2,3). At each stage of CKD, the risk of CVD mortality is several-fold higher than the risk of progression to end-stage renal disease (4). Despite intense investigation (5), the mechanisms responsible remain largely unknown.

Arterial calcification is one potential mechanism linking CKD and CVD. Arterial calcification is highly prevalent in...
maintenance dialysis patients (6–8), and its presence and severity predict all-cause mortality (9,10). However, vascular calcification may be caused by either intimal or medial arterial calcification (11,12). As part of the atherosclerotic process, calcium is deposited within the tunica intima with lipid-rich plaque and focal arterial narrowing. Alternatively, medial arterial calcification is limited to the tunica media, has a uniform character resembling a ring in vessel cross-section and tram-tracks in longitudinal view, is not inflammatory or flow limiting (12), and directly contributes to arterial stiffness in animal models (13,14). Medial arterial calcification is particularly prevalent in the distal arteries of the lower extremities and is correlated with higher pulse-wave velocity, left ventricular hypertrophy, and mortality in maintenance dialysis populations (9,11).

The ankle brachial index (ABI) is a noninvasive measure of subclinical CVD that may allow for determination of the predominant pattern of arterial disease in the lower limbs. A low ABI is sensitive and specific for angiographically determined atherosclerosis of the lower extremities (15,16), and is strongly associated with CVD events and mortality in a variety of populations (17–23). Alternatively, a high ABI reflects generalized stiffening of the lower limb arteries (24,25), and an elevated ankle systolic blood pressure has high specificity for medial arterial calcification (26). Recent studies show U-shaped relationships between ABI and mortality, wherein subjects with a high ABI had nearly equal mortality risk to subjects with a low ABI, and both groups were at approximately 2-fold mortality risk compared with subjects with intermediate ABI scores (27–29).

Although prior studies have shown that CKD is associated with a low ABI (30–33), the association of CKD with a high ABI has not been studied. Such an association would suggest that medial arterial calcification may begin early in the process of kidney dysfunction. Herein, we evaluate the association of CKD with a high ABI and compare the strength of association to that with a low ABI in the CHS (Cardiovascular Health Study), a community-based cohort of older adults. We hypothesized that CKD would be associated with both a low and a high ABI, independent of traditional CVD risk factors.

Methods

Participants. The CHS is a community-based study of older adults that was designed to evaluate risk factors for development and progression of CVD. Its study design has been described previously (34,35). In brief, eligibility required age ≥65 years, expectation to remain in the area for 3 years after recruitment, no active cancer treatment, and the ability to provide consent. Between 1989 and 1990, 5,201 participants were recruited from 4 communities (Sacramento, California; Forsyth County, North Carolina; Washington County, Maryland; and Allegheny County, Pennsylvania). An additional 687 African Americans were recruited in 1992 to 1993. Participants were sampled from Medicare eligibility lists in each area. The present study represents a cross-sectional analysis using data from the 1992 to 1993 study visit, at which ABI and kidney function were measured concurrently. Among the 5,265 subjects who participated in that visit, 488 (9%) were excluded because of missing ABI measurements, and 246 (5%) were excluded because of missing kidney function measurement, resulting in a study sample of 4,531 subjects for this analysis. All participants provided written informed consent, and the study was approved by the investigational review boards of the 4 clinical sites and the Data Coordinating Center at the University of Washington.

Measurements. Kidney Function. Fasting (8 h) blood specimens were collected at the 1992 to 1993 study visit, and were stored at −70°C. Cystatin C concentrations were measured using a BN II nephelometer (Dade Behring Inc., Deerfield, Illinois) as described elsewhere (36). The intra-assay and interassay coefficients of variation were <2.9% and <3.2%, respectively. Cystatin C–based estimated glomerular filtration rate (eGFR) was calculated using the equation: eGFR$_{CYS}$ = 76.7 · cystatin C [mg/l]$^{-1.19}$ (37).

Serum creatinine concentrations were measured using the Kodak Ektachem 700 Analyzer (Eastman Kodak, Rochester, New York), a colorimetric method. The intra-assay coefficient of variation was <2%. Creatinine measurements were indirectly calibrated to the reference standard at the Cleveland Clinical laboratory, the core laboratory of the MDRD (Modification of Diet and Renal Disease) study, as previously described (38). The abbreviated (4-variable) MDRD study formula was used to calculate creatinine-based eGFR (eGFR$_{MDRD}$) (39). CKD was defined by an eGFR <60 ml/min/1.73 m² by either equation (40).

ABI. The ABI protocol has been described previously (20). Briefly, after at least 5 min rest and with the subject in a supine position, standard mercury sphygmomanometers and a Doppler stethoscope (8 MHz, Huntleigh Technology, Inc., Luton, United Kingdom) determined the right brachial artery and right and left leg posterior tibial artery systolic blood pressures. Duplicate measurements were obtained and averaged. When a blood pressure could not be measured in the right arm, the left arm was used. The ratio of the systolic blood pressure in the leg to the arm defined the leg-specific ABI. The lower of the leg-specific ABIs was used as the patient-specific ABI for this analysis. When arterial flow was not abolished with the leg blood pressure cuff inflated to >300 mm Hg, the artery was deemed incompressible.
SECONDARY PREDICTORS. Age, sex, and race/ethnicity were determined by self report. After a 5-min rest, seated blood pressure was determined in duplicate using standard mercury sphygmomanometers (Hawksley & Sons Ltd., Sussex, United Kingdom) (41). Results were averaged. Prevalent hypertension was defined by a seated systolic blood pressure \( \geq 140 \) mm Hg, diastolic blood pressure \( \geq 90 \) mm Hg, or treatment for hypertension. Prevalent diabetes was defined by history of physician’s diagnosis, use of hypoglycemic agents or insulin, or fasting glucose level \( \geq 126 \) mg/dl. Smoking history was determined by questionnaire and categorized as current, past, or never. Height (cm) and weight (kg) were recorded without shoes and with the patient wearing light clothes, and body mass index was calculated (kg/m\(^2\)). The Olympus Demand System (Olympus, Lake Success, New York) determined serum total and high-density lipoprotein (HDL) cholesterol and triglyceride concentrations; low-density lipoprotein cholesterol concentrations were calculated using the Friedewald equation (42). The C-reactive protein (CRP) was determined by an ultrasensitive enzyme-linked immunosorbent assay as described previously (43,44).

Statistical analysis. We developed natural piecewise-cubic spline functions to evaluate parametric nonlinear functions for eGFR\(_{\text{cys}}\) and ABI measurements. Pre-specified interior knots were placed at the quartiles of the distribution of eGFR\(_{\text{cys}}\). Subjects with the 2.5% highest and lowest extreme eGFR\(_{\text{cys}}\) measurements were excluded from spline functions to avoid clinically implausible extrapolation by extreme values. Because prior studies consistently showed higher risk for all-cause mortality and CVD events among people with an ABI <0.9 or \( >1.4 \) (27–29), we developed mutually exclusive categories that simultaneously captured the functional form of the spline analysis and also utilized these cut points (<0.90, 0.90 to 1.09, 1.10 to 1.40, and >1.40/incompressible). Subjects with ABI measurements of 1.10 to 1.40 served as the reference group for subsequent analyses.

We compared the distribution of demographic characteristics and traditional CVD risk factors across ABI groups by analysis of variance for continuous variables and chi-square for categorical variables. When statistically significant differences were observed across groups, pairwise comparisons between groups were evaluated by the Student \( t \) test or Wilcoxon rank sum test for continuous variables, and by the chi-square test or Fisher exact test for categorical variables. We adjusted for multiple comparisons using the Holm-Sidak test (45).

Multinomial logistic regression evaluated the associations of CKD with a low and high ABI simultaneously. It uses a log-link rather than logit-link, and therefore provides estimates of the relative risk. The initial model was unadjusted, and a subsequent model was adjusted for age, sex, and race. The final model evaluated these variables and all other variables that were significantly different across ABI categories, providing a parsimonious list of covariates to facilitate comparison of the relative strength of associations of CKD with a high and low ABI. We performed sensitivity analyses evaluating ankle systolic blood pressure as the outcome, adjusting for the identical covariates and branchial blood pressure, because previous studies provide test characteristics of ankle blood pressure for medial arterial calcification rather than the high ABI (26). Results were similar, so data are presented for ABI only. Lastly, we created multiplicative interaction terms to evaluate whether the observed relationships differed by diabetes status, selected a priori because of prior published research (46,47). S-Plus (version 8.0) and SPSS statistical software (version 15.0.1.1) (SPSS, Inc., Chicago, Illinois) were used for the analyses.

Results

Among the 4,513 study participants, the mean age was 75 years, 58% were female, and 83% were Caucasian. The mean eGFR\(_{\text{cys}}\) was 73 ± 19, and the mean eGFR\(_{\text{MDRD}}\) was 76 ± 20 ml/min/1.73 m\(^2\), respectively. Chronic kidney disease was detected among 23% (n = 1,042) by eGFR\(_{\text{cys}}\), and 21% (n = 939) by eGFR\(_{\text{MDRD}}\). Thirteen percent of participants (n = 579) had ABI measurements <0.90, 33% (n = 1,478) had an ABI between 0.90 and 1.09, 51% (n = 2,304) had an ABI between 1.10 and 1.40, and 3% (n = 152) had an ABI >1.40 or incompressible. Fifty-seven participants were categorized in this latter group on the basis of incompressible lower limb arteries.

Compared with participants with an ABI 1.10 to 1.40, lower ABI participants were older; more frequently male and African American; had a higher prevalence of hypertension, diabetes, and tobacco use; and were more likely to have an atherogenic lipid profile and higher CRP levels (Table 1). In contrast, participants with a high ABI did not differ significantly by age or race. With the exception of male sex, diabetes, and lower HDL cholesterol, high ABI was not associated with traditional CVD risk factors. Participants with a high ABI had similar tobacco use and body mass index, and a lower prevalence of hypertension and lower total and low-density lipoprotein cholesterol, triglycerides, and CRP levels compared with the reference group.

We evaluated the association of kidney function as a continuous variable with ABI measurements. Adjusted spline functions showed a U-shaped relationship, wherein people with either a high or low ABI had a lower eGFR compared with people with intermediate ABI measurements (Fig. 1). Subjects with the most preserved kidney function (highest eGFR) were centered at an ABI measurement of 1.20.

When defined by eGFR\(_{\text{cys}}\) CKD was associated with an approximately 3-fold risk of an ABI <0.90, and an approximately 1.5-fold risk of an ABI >1.40 compared with subjects with ABI measurements of 1.10 to 1.40 in unadjusted analyses (Table 2). The association of CKD with ABI <0.90 was moderately attenuated in the fully adjusted model, but CKD remained significantly associated with a
 association of CKD with an ABI
In contrast, statistical adjustment
although less so for eGFR MDRD (interaction p values
became generally steeper among subjects with eGFR values
association at early decrements in kidney function that
associations became evident, we evaluated the association of
Discussion
The primary finding of this study is that moderate CKD is
associated with a high ABI in community-living older people. Participants with CKD had an approximately 50% greater risk of a high ABI in adjusted models, an association of approximately equal strength to the association of CKD with a low ABI. High ABI has predicted all-cause (27–29) of approximately equal strength to the association of CKD

Table 1 Participants Categorized by ABI*

<table>
<thead>
<tr>
<th>Measurements</th>
<th>&lt;0.90</th>
<th>0.90–1.10</th>
<th>1.10–1.40</th>
<th>&gt;1.40/Incompressible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>77 ± 6†</td>
<td>75 ± 5†</td>
<td>74 ± 5</td>
<td>75 ± 6</td>
</tr>
<tr>
<td>Female</td>
<td>292 (50)†</td>
<td>1.004 (68)†</td>
<td>1.266 (55)</td>
<td>54 (30)†</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>410 (71)†</td>
<td>1.182 (80)†</td>
<td>1.980 (86)</td>
<td>135 (89)</td>
</tr>
<tr>
<td>Black</td>
<td>163 (28)†</td>
<td>289 (20)†</td>
<td>312 (14)</td>
<td>17 (11)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (1)†</td>
<td>7 (1)†</td>
<td>12 (1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>428 (74)†</td>
<td>919 (62)†</td>
<td>1,155 (50)</td>
<td>63 (41)†</td>
</tr>
<tr>
<td>Diabetes</td>
<td>140 (24)†</td>
<td>216 (15)</td>
<td>300 (13)</td>
<td>34 (22)†</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>96 (17)†</td>
<td>179 (12)†</td>
<td>151 (7)</td>
<td>12 (8)</td>
</tr>
<tr>
<td>Past</td>
<td>284 (50)†</td>
<td>619 (43)†</td>
<td>1,007 (45)</td>
<td>74 (49)</td>
</tr>
<tr>
<td>Never</td>
<td>189 (33)†</td>
<td>645 (45)†</td>
<td>151 (7)</td>
<td>65 (43)</td>
</tr>
<tr>
<td>Measurements</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26.2 ± 4.7</td>
<td>26.4 ± 4.6†</td>
<td>27.2 ± 4.7</td>
<td>27.1 ± 5.2</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>144 ± 24†</td>
<td>140 ± 22†</td>
<td>133 ± 19</td>
<td>126 ± 25†</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>70 ± 13†</td>
<td>72 ± 12</td>
<td>71 ± 11</td>
<td>68 ± 11†</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>215 ± 43</td>
<td>211 ± 37†</td>
<td>207 ± 37</td>
<td>195 ± 38†</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>134 ± 38†</td>
<td>128 ± 33</td>
<td>126 ± 33</td>
<td>119 ± 34</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>50 ± 14†</td>
<td>55 ± 15†</td>
<td>53 ± 14</td>
<td>51 ± 13</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>133 (94–194)†</td>
<td>123 (90–174)</td>
<td>122 (88–169)</td>
<td>117 (86–153)</td>
</tr>
<tr>
<td>Creatinine (mg/l)</td>
<td>3.9 (1.8–8.4)†</td>
<td>2.8 (1.3–6.4)†</td>
<td>2.4 (1.1–5.3)</td>
<td>1.9 (0.9–4.7)</td>
</tr>
</tbody>
</table>

Values are n (%), mean ± SD, or median [interquartile range]. *Across-group p values were <0.001 for all comparisons. †p < 0.01 compared with the ABI 1.10 to 1.40 category (Sidak adjusted). ‡p < 0.05 compared with the ABI 1.10 to 1.40 category (Sidak adjusted).

ABI = ankle brachial index; eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MDRD = Modification of Diet and Renal Disease.

2-fold risk of a low ABI. In contrast, statistical adjustment for traditional CVD risk factors had a minimal effect on the association of CKD with an ABI >1.40. Results were similar when CKD was defined by creatinine, as well as in companion analyses that evaluated ankle systolic blood pressure as the dependent variable, rather than ABI (data not shown).

To determine the severity of CKD at which these associations became evident, we evaluated the association of kidney function as a continuous measure with a low and high ABI. For each outcome, there was a modest linear association at early decrements in kidney function that became generally steeper among subjects with eGFR values <80 ml/min/1.73 m² (Fig. 2).

Next, we evaluated the association of each kidney function measure with the ABI categories, stratified by diabetes status. The associations of CKD with a low ABI seemed similar in people with or without diabetes (Table 3). The association of CKD with a high ABI, however, was qualitatively stronger among people with diabetes, and the interaction was of borderline significance for eGFR$_{cys}$, although less so for eGFR$_{MDR}$ (interaction p values = 0.07 and = 0.24, respectively). Because of the small numbers in the high ABI group, the power to detect such an interaction was low.
function not sufficiently severe to result in elevated serum creatinine levels were strongly associated with future CVD events in the CHS cohort. The mechanisms responsible for this relatively strong association despite only modest decrements in kidney function remain uncertain. Therefore, if the association of mild kidney dysfunction and a high ABI is confirmed, future studies elucidating the responsible mechanisms may provide novel insights into the link between CKD and CVD events.

Medial arterial calcification is thought to lead to high ABI measurements in the majority of cases (24,25). Indeed, Young et al. (26) showed that high ABI scores directly correlated with medial arterial calcification severity as determined by lower limb plain X-ray, and that an ankle systolic blood pressure ≥190 mm Hg had >90% specificity for X-ray–determined medial arterial calcification. Medial arterial calcification is characterized by a diffuse distribution that may directly contribute to arterial stiffness (13,14,48,49). Among maintenance dialysis patients, medial arterial calcification has been associated with increased left ventricular mass and aortic pulse-wave velocity (13), which may lead to cardiac fibrosis and increased arrhythmia risk. If similar relations extend to people without severe kidney disease, a high ABI might indicate elevated risk for CVD events and mortality by mechanisms entirely distinct from atherosclerosis. These hypotheses require future study, but may be particularly relevant in people with CKD, in whom the prevalence of

<table>
<thead>
<tr>
<th>ABI Groups</th>
<th>&lt;0.90</th>
<th>0.90–1.10</th>
<th>1.10–1.40 (Reference)</th>
<th>&gt;1.40/Incompressible</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>579 (13)</td>
<td>1,478 (33)</td>
<td>2,304 (51)</td>
<td>152 (3)</td>
</tr>
<tr>
<td>Moderate CKD by cystatin-based eGFR (n = 1,042, 23%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>3.07 (2.53–3.74)</td>
<td>1.22 (1.03–1.43)</td>
<td>—</td>
<td>1.65 (1.14–2.38)</td>
</tr>
<tr>
<td>Age, sex, race adjusted</td>
<td>2.55 (2.06–3.15)</td>
<td>1.18 (1.00–1.40)</td>
<td>—</td>
<td>1.57 (1.06–2.32)</td>
</tr>
<tr>
<td>Fully adjusted†</td>
<td>2.00 (1.60–2.51)</td>
<td>1.11 (0.93–1.33)</td>
<td>—</td>
<td>1.55 (1.04–2.33)</td>
</tr>
<tr>
<td>Moderate CKD by MDRD-based eGFR (n = 936, 21%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unadjusted</td>
<td>2.12 (1.73–2.61)</td>
<td>1.19 (1.01–1.41)</td>
<td>—</td>
<td>1.43 (0.97–2.10)</td>
</tr>
<tr>
<td>Age, sex, race adjusted</td>
<td>1.83 (1.48–2.28)</td>
<td>1.13 (0.96–1.34)</td>
<td>—</td>
<td>1.45 (0.97–2.16)</td>
</tr>
<tr>
<td>Fully adjusted†</td>
<td>1.59 (1.26–2.01)</td>
<td>1.07 (0.90–1.28)</td>
<td>—</td>
<td>1.50 (1.00–2.24)</td>
</tr>
</tbody>
</table>

Values are relative risk (95% confidence interval) unless otherwise specified. *Defined as eGFR ≤60 ml/min/1.73 m². †Adjusted for age, sex, hypertension, diabetes, smoking, BMI, LDL, HDL, and CRP.

BMI = body mass index; CKD = chronic kidney disease; CRP = C-reactive protein; other abbreviations as in Table 1.
arterial calcification is high (50,51) and in whom traditional CVD risk factors only partially account for CVD risk (2,52).

Although a high ABI may identify individuals at higher risk for CVD events, it is uncertain whether or not this association is entirely independent of atherosclerosis. Atherosclerotic peripheral arterial disease (PAD) and medial arterial calcification may coexist within individuals (53,54). When this occurs, the stiff lower limb arteries may increase the ABI measurements, thus precluding the detection of atherosclerotic disease via a low ABI. Therefore, the associations of a high ABI with CKD in this analysis, and with CVD events and all-cause mortality in prior reports, may in part reflect residual confounding by undetected peripheral atherosclerosis. Future studies with confirmatory tests for atherosclerotic PAD that are less affected by concomitant medial arterial calcification, such as toe brachial index measurement (25), are required to evaluate the contribu-

**Figure 2** The Association of the Spectrum of GFR With Low and High Ankle Brachial Index

Natural cubic spline function. The solid line represents relative risk, and dotted lines represent 95% confidence intervals. Both spline functions were adjusted for age, sex, race/ethnicity, hypertension, diabetes, smoking, body mass index, low-density lipoprotein, high-density lipoprotein, and C-reactive protein. Abbreviation as in Figure 1.
With the exception of age, diabetes, and lower HDL, traditional CVD risk factors were not associated with a high ABI in this study. Similar findings have been observed in other community-based studies (28,29). Future research should evaluate risk factors for high ABI and, by extension, risk factors for arterial stiffness. Small studies among people with advanced CKD have suggested that alterations in mineral metabolism may be associated with medial arterial calcification or a high ABI (13,55). Whether or not such associations extend to populations with normal to moderate decrements in kidney function is unknown. In addition, future studies should evaluate the associations of a high ABI with cardiac structure and function, both at rest and with stress, because prior studies suggest that subjects with a high ABI may have a more pronounced vasoreactive response to exercise (56).

Strengths of this study include its community-based setting, large sample size, and uniform measurement of creatinine, cystatin C, ABI, and multiple potential confounding variables. The simultaneous availability of creatinine and cystatin C has specific advantages. The eGFR by creatinine is commonly available in clinical practice and many observational studies, improving the generalizability of our study and allowing comparison of strengths of association across studies if these associations are evaluated in other settings in the future. Alternatively, cystatin C provides a more accurate measure of kidney function among people with normal or near-normal kidney function (57–60), the range of kidney function observed in the majority of CHS study participants. Its availability in this study allows us to evaluate more accurately whether or not early decrements in kidney function were associated with a high and low ABI.

This study also has important limitations. First, the cross-sectional study design does not allow evaluation of temporality. Next, we lacked albuminuria measurements. A prior study showed that albuminuria was associated with a high ABI in bivariate analysis, but this was not subjected to multivariable models, an area that requires further investigation (61). The ABI was defined by right arm blood pressures and without dorsalis pedis blood pressures. This may have introduced some misclassification in ABI categories. Future studies should include both ABI and toe brachial index measurements to evaluate more completely the respective associations of atherosclerotic PAD and arterial stiffness with CVD events. Next, because the prevalence of a high ABI was only 3% (n = 152) in our study sample, we had imprecise estimates of strengths of association, as shown by relatively wide confidence intervals (Table 2). This was particularly true when analyses were stratified by diabetes status. Although the association of CKD with a high ABI was qualitatively stronger in people with diabetes, future studies are required to determine whether this observation is reproducible. Last, participants in this study were older and were community-living, and few had advanced CKD. Results may not be generalizable to younger people or to those with late-stage CKD.

Conclusions

We show that diminished kidney function is associated with high ABI measurements. The relationship of kidney function with a high ABI was not explained by traditional CVD risk factors. Although much is known about risk factors and consequences of atherosclerotic PAD, future studies are needed to elucidate mechanisms leading to high ABI and medial arterial calcification and to understand mechanisms linking them to CVD events. Such studies may ultimately provide novel insights into the mechanisms of CVD in subjects with kidney disease.

Acknowledgments

A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm.
REFERENCES


Key Words: kidney disease ● chronic ● atherosclerosis ● calcium ● cardiovascular disease ● arterial stiffness.